The reliability of 11C Acetate as tracer for prostate cancer remains an object of debate for clinicians.
AIM OF THE STUDY was to evaluate the accuracy of 11C Acetate PET/CT in restaging patients with previous history of prostate adenocarcinoma who faced biochemical relapse after early radical treatment.
We retrospectively evaluate 138pts (mean age 70 ± 7 y), with biochemical suspect of relapse, who underwent 11C Acetate PET/CT
RESULTS: PET/CT scan was positive in 95 pts (69%). Receiver operating characteristic (ROC) analysis showed that the highest accuracy (sensitivity 73 %, specificity 79%) was achieved when prostate-specific antigen (PSA) value of 1.87 ng/ml was used as cutoff value for interpreting the results (p <0.0001 and the area under the ROC curve AUC = 0.833). All pts treated with radiotherapy showed a positive PET/CT scan. The cutoff value for pts treated with prostatectomy was 2.25 ng/ml (sensitivity 60%, specificity 81%). However, in this last group analyzing only pts out-off androgen-deprivation therapy the cutoff decreased at 1.87 ng/ml (sensitivity 75%, Specificity 87%).
11C Acetate PET/CT is a useful tool in patients affected by prostate cancer with suspected relapse due to PSA elevation. The highest accuracy is reached evaluating pts with previous prostatectomy, without androgen-deprivation therapy and PSA cutoff level of 1.87 ng/ml.